Epigral Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹746 Cr +27.1% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
E

Epigral Ltd

Q1 FY26Chemicals & Petrochemicals

Epigral Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹607Cr
−6.8% YoY
−3.3% QoQ
Net profit
₹160Cr
+86% YoY
+83.9% QoQ
Margin
27%
0 pp YoY
−1 pp QoQ
Price₹1,126
Market cap₹4.8K Cr
P/E17.8

The short version

Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries. Epigral targets consistent growth driven by expansion and diversification into multiproduct segments catering to various industries.

From Epigral Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries.
  • Revenue contribution from derivatives and specialty business is targeted to increase from 50% in Q1 FY26 to 70% by FY28.
  • The recently commissioned Chlorotoluene value chain is expected to generate sizable revenue by the end of FY26, with commercial order clarity by Q4 FY26.
  • Expansion projects including doubling capacities of CPVC resin and Epichlorohydrin (ECH) are on schedule, expected to boost volumes and sales in FY27 and FY28.
  • New product evaluations and projects on existing and newly acquired land at Dahej aim to add growth beyond 2028, focusing on import substitution chemicals with expected double-digit CAGR (~12-13%) over 10 years.

2 more points from Epigral Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Epigral Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Epigral is currently executing capex projects including doubling the capacity of CPVC resin and Epichlorohydrin plants.
  • A 19.8 MW wind-solar hybrid power plant expansion is underway, expected to add to a total of 38 MW hybrid capacity.
  • Ongoing expansion capex for FY '26 is around INR 450 crores, with roughly INR 120 crores already spent; a similar capex range (~INR 400-450 crores) is expected for FY '27.
  • Company is evaluating a project within the existing complex to optimize infrastructure; this will be the last at this site.

2 more points from Epigral Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Pipeline customers for chlorine include Meghmani company and other nearby companies supplied via pipeline; chlorine is partly sold through pipeline and partly to the general market.
  • Trial orders for Chlorotoluenes are ongoing, commercial scale ramp-up anticipated by end of Q3 FY '26.
  • The company expects consistent growth in its multiproduct pipeline aligned with expansion and diversification strategies.

Epigral Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Epigral Ltd Q1 FY26 results — key figures

Epigral Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue607651-6.8%628-3.3%
Operating profit (EBITDA)163176-7.4%173-5.8%
Operating margin27%27%0 pp28%-1 pp
Profit before tax107131-18.3%131-18.3%
Net profit (PAT)16086+86%87+83.9%
EPS (₹)37.1820.70+79.6%20.08+85.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Balaji Amines (Q1 FY26)

    Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…

  • Linde India (Q1 FY26)

    Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…

  • Vidhi Specialty (Q1 FY26)

    87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • Chemcon Speciality Chemicals (Q1 FY26)

    Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Epigral Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Epigral Ltd Q1 FY26 results?

Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries. Epigral targets consistent growth driven by expansion and diversification into multiproduct segments catering to various industries.

What is Epigral Ltd share price analysis?

Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.

Is Epigral Ltd planning capital expenditure?

Epigral is currently executing capex projects including doubling the capacity of CPVC resin and Epichlorohydrin plants.

Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.